COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.

Citation data:

Molecular cancer therapeutics, ISSN: 1538-8514, Vol: 17, Issue: 2, Page: 474-483

Publication Year:
Usage 3
Abstract Views 3
Captures 5
Readers 5
Repository URL:
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong; Yu, Weimin; Zimmermann, Maike; Yang, Jun; Hwang, Sung Hee; Zhu, Daniel; Lin, Tzu-Yin; Malfatti, Michael; Turteltaub, Kenneth W; Henderson, Paul T; Airhart, Susan; Hammock, Bruce D; Yuan, Jianlin; de Vere White, Ralph W; Pan, Chong-Xian Show More Hide
American Association for Cancer Research (AACR)
Medicine; Biochemistry, Genetics and Molecular Biology; Life Sciences; Medicine and Health Sciences
article description
Cisplatin-based therapy is highly toxic, but moderately effective in most cancers. Concurrent inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) results in antitumor activity and has organ-protective effects. The goal of this study was to determine the antitumor activity of PTUPB, an orally bioavailable COX-2/sEH dual inhibitor, in combination with cisplatin and gemcitabine (GC) therapy. NSG mice bearing bladder cancer patient-derived xenografts were treated with vehicle, PTUPB, cisplatin, GC, or combinations thereof. Mouse experiments were performed with two different PDX models. PTUPB potentiated cisplatin and GC therapy, resulting in significantly reduced tumor growth and prolonged survival. PTUPB plus cisplatin was no more toxic than cisplatin single-agent treatment as assessed by body weight, histochemical staining of major organs, blood counts, and chemistry. The combination of PTUPB and cisplatin increased apoptosis and decreased phosphorylation in the MAPK/ERK and PI3K/AKT/mTOR pathways compared with controls. PTUPB treatment did not alter platinum-DNA adduct levels, which is the most critical step in platinum-induced cell death. The study using the combination index method showed modest synergy between PTUPB and platinum agents only in 5637 cell line among several cell lines examined. However, PTUPB is very active by inhibiting angiogenesis. In conclusion, PTUPB potentiated the antitumor activity of cisplatin-based treatment without increasing toxicity and has potential for further development as a combination chemotherapy partner. .